Results 131 to 140 of about 28,984 (253)

HIF2A as a prognostic and clinical therapeutic target in ovarian clear cell carcinoma

International Journal of Cancer, Volume 158, Issue 11, Page 2957-2971, 1 June 2026.
What's new? Ovarian clear cell carcinoma is highly associated with hypoxia. Hypoxia‐inducible factor 2A (HIF2A) is a key regulator of hypoxic responses, but its role in ovarian clear cell carcinoma remains unclear. This study demonstrated the unfavorable prognostic significance of HIF2A expression in ovarian clear cell carcinoma.
Mengxin Jiang, Ken Yamaguchi, Kohei Hamada, Yuko Hosoe, Yuka Mise, Sachiko Kitamura, Zhihong Liu, Hairong Wei, Zhenhai Gao, Mana Taki, Koji Yamanoi, Ryusuke Murakami, Rin Mizuno, Taito Miyamoto, Junzo Hamanishi, Masaki Mandai   +15 more
wiley   +1 more source

A mechanistic‐based normal tissue complication probability (NTCP) prediction through a microdosimetry‐based multiscale radiation biophysical model (MS‐GSM2)

Precision Radiation Oncology, EarlyView.
Marco Battestini, Marta Missiaggia, Giulio Bordieri, Jules Morand, Emanuele Scifoni, Francesco Giuseppe Cordoni   +5 more
wiley   +1 more source

Evaluation of Hemoadsorption Capacity of the CytoSorb Adsorber for Toxic Doses of Diclofenac and Meloxicam in Porcine Plasma

Journal of Clinical Apheresis, Volume 41, Issue 3, June 2026.
ABSTRACT The objective of this in vitro experimental was to determine the utility of hemoadsorption (HA) using the CytoSorb adsorber to remove meloxicam and diclofenac from porcine plasma. For this purpose 12 1‐L aliquots of porcine plasma, 6 units were spiked with 293 μg/mL (262–320 μg/mL) diclofenac and 6 with 42.8 μg/mL (41.4–44.7 μg/mL) meloxicam ...
Bettina Giani, René Dörfelt, Katrin Hartmann, Florian Sänger   +3 more
wiley   +1 more source

Fast microdosimetry algorithms in particle therapy: Benchmark and applicability guidelines

Precision Radiation Oncology, EarlyView.
Giorgio Cartechini, Marta Missiaggia, Francesco Giuseppe Cordoni   +2 more
wiley   +1 more source

Oxidative Stress and DNA Epigenetic Modifications in Cancer: Mechanisms and Targeted Therapeutics

MedComm – Oncology, Volume 5, Issue 2, June 2026.
Reactive oxygen species (ROS) modulate DNA methyltransferases (DNMTs), ten‐eleven translocation family proteins (TETs) and their cofactors, reshaping 5‐methylcytosine (5mC)/5‐hydroxymethylcytosine (5hmC)/5‐formylcytosine (5fC) landscapes and gene expression in cancer cells. In turn, epigenetic control of antioxidant and metabolic pathways feeds back on
Xishan Yang, Qitai Chen, YuJie Yu, Yi Zang, Rujia Zheng, Zhe Zhang, Shuaijun Lu, Li Zhou   +7 more
wiley   +1 more source

Overview of carbon ion radiotherapy

Overview of carbon ion radiotherapy
In cancer radiotherapy (RT), ion beams such as proton and carbon ion beams have unique characteristics of improved dose distributions, enabling a delivery of sufficient dose to the target volume while minimizing the dose in the surrounding normal tissues. In addition, carbon ions being heavier than protons provide a higher biological effectiveness with
openaire   +1 more source

Advantages, limitations, and future perspectives of using TEPCs in clinical quality assurance

Precision Radiation Oncology, EarlyView.
Anna Bianchi, Anna Selva, Valeria Conte
wiley   +1 more source

Oxidative Stress in the Tumor Immune Microenvironment: Mechanisms and Therapeutic Perspectives

MedComm – Oncology, Volume 5, Issue 2, June 2026.
Oxidative stress is involved in several key processes in cancer, including redox regulation, DNA damage, post‐translational modifications, transcriptional regulation, epigenetic modifications, metabolic reprogramming, cell death, and immune modulation. These mechanisms collectively influence tumor progression, immune evasion, and therapeutic responses,
Zhen Wang, Bowen Li, Pan Tang, Fanchen Yan, Shuxin Wang, Guiying Leng, Panduo Dawa, Yuansi Chen, Yihan Guo, Pan Yang, Yi Li, Siyu Liu, Erdan Dong, Siyuan Qin, Zhoufeng Wang   +14 more
wiley   +1 more source

Experimental and computational characterisation of the secondary fragment field in clinical proton therapy beams using microdosimetry

Precision Radiation Oncology, EarlyView.
Gabriele Parisi, Marta Missiaggia, Enrico Pierobon, Francesco Cordoni, Enrico Verroi, Claudio Verona, Giuseppe Schettino, Chiara La Tessa   +7 more
wiley   +1 more source

Clinicopathological characteristics of patients with inoperable non‐small cell lung cancer harboring circulating NRF2 pathway mutations

The Journal of Pathology, Volume 269, Issue 2, Page 164-181, June 2026.
Abstract Lung cancer is the leading cause of global cancer‐related morbidity and mortality, with tobacco smoking as its strongest risk factor. Nuclear factor erythroid 2‐related factor 2 (NRF2) is a redox‐regulated transcription factor frequently dysregulated in non‐small cell lung cancer (NSCLC), leading to aggressive disease and resistance to therapy.
Jouni Härkönen, Satu Tiainen, Jouni Kujala, Linnea Muhonen, Ponnuswamy Mohanasundaram, Tuomas Tikkanen, Ina Pöhner, Tommi Patinen, Simone Adinolfi, Juha P Väyrynen, Päivi Auvinen, Arto Mannermaa, Petri Pölönen, Tuomas Rauramaa, Anna‐Liisa Levonen   +14 more
wiley   +1 more source